Pralsetinib in Metastatic Solid Tumor: NCT07704658 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 4
Clinical phase
Recruiting
Recruitment status
12
Planned enrollment
2027-07-30
Primary-completion proxy
Executive view
NCT07704658 evaluates Pralsetinib in Metastatic Solid Tumor. The disclosed sponsor is Rigel Pharmaceuticals, Inc., the design is Interventional, and the geographic footprint is Spain. The first listed primary endpoint is Area Under the Plasma Concentration-Time Curve from zero to infinity (AUC0-inf), assessed over Up to 48 hours post-dose or as appropriate for each probe substrate.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07704658 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Metastatic Solid Tumor landscape. Drug & Asset MCP drug_fetch was queried for Pralsetinib, while Company & Deal Intelligence MCP organization_fetch was queried for Rigel Pharmaceuticals, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07704658 | Pralsetinib | Phase 4 / Recruiting | Rigel Pharmaceuticals, Inc. | Spain | Area Under the Plasma Concentration-Time Curve from zero to infinity (AUC0-inf) Up to 48 hours post-dose or as appropriate for each probe substrate | 2027-07-30 |
| NCT07702305 | Sacituzumab tirumotecan | Phase 1 / Not yet recruiting | Henan Cancer Hospital | Geography not reported | Drug Safety Assessments are performed before each dose, and monitoring continues… | 2027-12-31 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07704658 is a Phase 4, recruiting study with 12 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Area Under the Plasma Concentration-Time Curve from zero to infinity (AUC0-inf)” over “Up to 48 hours post-dose or as appropriate for each probe substrate.” The retrieved endpoint description is: To evaluate the effect of pralsetinib on the overall exposure of CYP3A4, CYP2C8, and CYP2C9, probe substrates, and hormonal contraceptive by measuring AUC0-inf for each probe substrate and its relevant metabolites..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 12 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Metastatic Solid Tumor. These records do not establish direct evidence for NCT07704658 unless the registration number matches.
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Phase 2; n=38; N2 Nodal Clearance (N2NC) = 73.3 percentage of participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04062708
Randomized Phase II Study of Pembrolizumab 200mg every12 Weeks Versus Every 3 Weeks in NSCLC With Clinical Benefit to Pembrolizumab Monotherapy: Multicenter International Study
Phase 2; n=9; 1-year Progression-free Survival (PFS) = 4 Participants ; 1-year Progression-free Survival (PFS) = 2 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04032418
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
Phase 3; n=1415; Compare Disease Free Survival (DFS) for Patients With NSCLC That is PD-L1 Expression TC ≥ 25% and Patients Without EGFR Exon 21 L858R Mutation or Exon 19 Deletions or ALK Gene Rearrangements(Median) = 60.2 DFS time in months. (95% Confidence Interval, 47.7 - NA); Compare Disease Free Survival (DFS) for Patients With NSCLC That is PD-L1 Expression TC ≥ 25% and Patients Without EGFR Exon 21 L858R Mutation or Exon 19 D… Source: https://clinicaltrials.gov/ct2/show/results/NCT02273375
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Pralsetinib is indexed as Small molecule drug with RET biology and a global stage of Approved. The asset profile lists Blueprint Medicines Corp. as an originator or developer.
Rigel Pharmaceuticals, Inc. is indexed in United States with the website http://www.rigel.com. Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases. The record lists 20 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Pralsetinib is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07704658
Protocol source: https://clinicaltrials.gov/study/NCT07704658
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.
Pralsetinib in Metastatic Solid Tumor is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Area Under the Plasma Concentration-Time Curve from zero to infinity (AUC0-inf) and 2027-07-30 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
